The Journal of Immunology, Vol 156, Issue 1 208-217, Copyright © 1996 by American Association of Immunologists

ARTICLES

Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma

A Anichini, R Mortarini, C Maccalli, P Squarcina, K Fleischhauer, L Mascheroni and G Parmiani
Division of Experimental Oncology D, National Tumor Institute, Milan, Italy.

To determine whether HLA-A21 restricted melanoma Ags exist that are not expressed on normal melanocytes, a panel of 478 T cell clones from six HLA-A21+ patients was selected for HLA-A2 restricted lysis of autologous tumor and then tested for differential recognition of HLA- A2.1+ melanomas and normal melanocytes. Four subsets of clones were identified in the panel of 107 HLA-A2-restricted CTL clones. CTL clones from three of the four subsets did not lyse melanocytes, but recognized fresh HLA-A2.1+ melanomas and defined three classes of epitopes, including unique Ags, common melanoma Ags, and Ags shared with neoplastic cells of different histologic origin. These CTL clones did not recognize any of the 10 peptides selected for specific association to HLA-A2.1 and derived from Melan-A/Mart-1, tyrosinase, gp100, or MAGE- 3 proteins. By contrast, the fourth subset of HLA-A2.1-restricted CTl clones recognized both melanoma and melanocytes. These CTL clones were directed to a peptide from either Melan-A/Mart-1, tyronise, or gp100. By a limiting dilution assay, designed to evaluate the frequency of HLA- A2-restricted CTL precursors (CTLp) directed to melanoma but not to melanocytes, such precursors were found in the peripheral blood or tumor site of five of six HLA-A2.1+ melanoma patients, and their frequency was much higher than the frequency of CTLp recognizing both tumor cells and the melanocytes. These results suggest that in melanoma patients most of the HLA-A2.1-restricted immune repertoire to melanoma is directly to epitopes expressed in the neoplastic but not in the normal cells of the melanocyte lineage.

This article has been cited by other articles:

				M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]

				V. Lennerz, M. Fatho, C. Gentilini, R. A. Frye, A. Lifke, D. Ferel, C. Wolfel, C. Huber, and T. Wolfel The response of autologous T cells to a human melanoma is dominated by mutated neoantigens PNAS, November 1, 2005; 102(44): 16013 - 16018. [Abstract] [Full Text] [PDF]

				M. Zanon, A. Piris, I. Bersani, C. Vegetti, A. Molla, A. Scarito, and A. Anichini Apoptosis Protease Activator Protein-1 Expression Is Dispensable for Response of Human Melanoma Cells to Distinct Proapoptotic Agents Cancer Res., October 15, 2004; 64(20): 7386 - 7394. [Abstract] [Full Text] [PDF]

				M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al. Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390. [Abstract] [Full Text] [PDF]

				R. Soiffer, F. S. Hodi, F. Haluska, K. Jung, S. Gillessen, S. Singer, K. Tanabe, R. Duda, S. Mentzer, M. Jaklitsch, et al. Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 2003; 21(17): 3343 - 3350. [Abstract] [Full Text] [PDF]

				I. D. Davis, M. Jefford, P. Parente, and J. Cebon Rational approaches to human cancer immunotherapy J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29. [Abstract] [Full Text] [PDF]

				O. Salvucci, M. Carsana, I. Bersani, G. Tragni, and A. Anichini Antiapoptotic Role of Endogenous Nitric Oxide in Human Melanoma Cells Cancer Res., January 1, 2001; 61(1): 318 - 326. [Abstract] [Full Text]

				R. Mortarini, A. Borri, G. Tragni, I. Bersani, C. Vegetti, E. Bajetta, S. Pilotti, V. Cerundolo, and A. Anichini Peripheral Burst of Tumor-specific Cytotoxic T Lymphocytes and Infiltration of Metastatic Lesions by Memory CD8+ T Cells in Melanoma Patients Receiving Interleukin 12 Cancer Res., July 1, 2000; 60(13): 3559 - 3568. [Abstract] [Full Text]

				T. A. Colella, T. N.J. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard Self-Tolerance to the Murine Homologue of a Tyrosinase-derived Melanoma Antigen: Implications for Tumor Immunotherapy J. Exp. Med., April 3, 2000; 191(7): 1221 - 1232. [Abstract] [Full Text] [PDF]

				D. Boczkowski, S. K. Nair, J.-H. Nam, H. K. Lyerly, and E. Gilboa Induction of Tumor Immunity and Cytotoxic T Lymphocyte Responses Using Dendritic Cells Transfected with Messenger RNA Amplified from Tumor Cells Cancer Res., February 1, 2000; 60(4): 1028 - 1034. [Abstract] [Full Text]

				W. Herr, E. Ranieri, A. Gambotto, L. S. Kierstead, A. A. Amoscato, L. Gesualdo, and W. J. Storkus Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4+ or CD8+ T lymphocytes from human blood PNAS, October 12, 1999; 96(21): 12033 - 12038. [Abstract] [Full Text] [PDF]

				A. Anichini, A. Molla, R. Mortarini, G. Tragni, I. Bersani, M. Di Nicola, A. M. Gianni, S. Pilotti, R. Dunbar, V. Cerundolo, et al. An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (CTL)-defined, Melanocyte-specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-specific CTLs but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions J. Exp. Med., September 6, 1999; 190(5): 651 - 668. [Abstract] [Full Text] [PDF]

				Z. Wang, F. M. Marincola, L. Rivoltini, G. Parmiani, and S. Ferrone Selective Histocompatibility Leukocyte Antigen (HLA)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624MEL28 Melanoma Cells J. Exp. Med., July 19, 1999; 190(2): 205 - 216. [Abstract] [Full Text] [PDF]

				M. A. Imro, S. Manici, V. Russo, G. Consogno, M. Bellone, C. Rugarli, C. Traversari, and M. P. Protti Major Histocompatibility Complex Class I Restricted Cytotoxic T Cells Specific for Natural Melanoma Peptides Recognize Unidentified Shared Melanoma Antigen(s) Cancer Res., May 1, 1999; 59(10): 2287 - 2291. [Abstract] [Full Text] [PDF]

				J. H. Sampson THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif. Neuro-oncol, January 1, 1999; 1(1): 33 - 42. [PDF]

				J. Wang, S. Saffold, X. Cao, J. Krauss, and W. Chen Eliciting T Cell Immunity Against Poorly Immunogenic Tumors by Immunization with Dendritic Cell-Tumor Fusion Vaccines J. Immunol., November 15, 1998; 161(10): 5516 - 5524. [Abstract] [Full Text] [PDF]

				R. Lupetti, P. Pisarra, A. Verrecchia, C. Farina, G. Nicolini, A. Anichini, C. Bordignon, M. Sensi, G. Parmiani, and C. Traversari Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage J. Exp. Med., September 21, 1998; 188(6): 1005 - 1016. [Abstract] [Full Text] [PDF]

				M. Gueguen, J.-J. Patard, B. Gaugler, F. Brasseur, J.-C. Renauld, P. J. Van Cangh, T. Boon, and B. J. Van den Eynde An Antigen Recognized by Autologous CTLs on a Human Bladder Carcinoma J. Immunol., June 15, 1998; 160(12): 6188 - 6194. [Abstract] [Full Text] [PDF]